Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Currently, 7.4% of the shares of the company are short sold. Based on an average trading volume of 171,900 shares, the short-interest ratio is presently 7.4 days.

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO traded down $0.06 during mid-day trading on Thursday, hitting $4.79. 64,370 shares of the company traded hands, compared to its average volume of 123,466. The stock's fifty day moving average price is $4.59 and its 200-day moving average price is $4.75. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company's stock worth $45,000 after acquiring an additional 5,367 shares during the period. Beaird Harris Wealth Management LLC raised its stake in Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company's stock valued at $70,000 after purchasing an additional 9,950 shares during the period. State Street Corp boosted its stake in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company's stock worth $232,000 after purchasing an additional 17,967 shares during the period. Bank of New York Mellon Corp purchased a new stake in Telomir Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, Suncoast Equity Management raised its position in shares of Telomir Pharmaceuticals by 109.9% during the third quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock valued at $329,000 after buying an additional 26,803 shares during the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.